$9.33
-0.42-4.31%
Last update: Nov 4, 4:00 PM

The average analyst price target for Climb Bio is $24.79, 166.8% above the current price. Of 15 analysts, 15 rate it Buy. Targets range from $9 to $35. The latest change came on Oct 20, 2026, when Deutsche Bank initiated coverage of Climb Bio with a Buy rating and a $28 price target.
Price Target Range — 7 Quarters
Analyst Consensus — 15 Analysts
Rating Trend — Last 9 Months